| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On August 6, 2004
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 2000N-1571
|
| Enrofloxacin for Poultry: Opportunity for Hearing
|
|
|
|
|
| 2003D-0383
|
| Draft Guidance for Industry and FDA Staff; Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use; Availability
|
|
|
|
|
| 2004N-0246
|
| Agency Emergency Processing Under OMB Review; Experimental Study of Qualified Health Claims for Glucosamine/Chondroitin
|
|
|
|
|
| 2004N-0331
|
| Determination That Esmolol Hydrochloride Injection and Ketorolac Tromethamine Injection Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
|
|
|
|
|
| 2004N-0337
|
| Subpart D IRB Referral, Effects of a Single Dose of Dextroamphetamine in Attention Deficit Hyperactivity Disorder; A Functional Magnetic Resonance Study.
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| LET
14189
|
| Golden Temple of Oregon, Inc.
|
| Vol #:
|
| 123
|
|
|
|
|
| 2000N-1571
|
| Enrofloxacin for Poultry: Opportunity for Hearing
|
|
|
|
|
| C
268
|
| Fieldale Farms Corporation
|
| Vol #:
|
| 99
|
|
|
|
|
| 2003D-0383
|
| Draft Guidance for Industry and FDA Staff; Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use; Availability
|
|
|
|
|
| N
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004N-0246
|
| Agency Emergency Processing Under OMB Review; Experimental Study of Qualified Health Claims for Glucosamine/Chondroitin
|
|
|
|
|
| NWL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004N-0331
|
| Determination That Esmolol Hydrochloride Injection and Ketorolac Tromethamine Injection Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
|
|
|
|
|
| N
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004N-0337
|
| Subpart D IRB Referral, Effects of a Single Dose of Dextroamphetamine in Attention Deficit Hyperactivity Disorder; A Functional Magnetic Resonance Study.
|
|
|
|
|
| NM
1
|
| FDA
|
| Vol #:
|
| 1
|
|
